DS
NAGE

David Shaw’s Niagen Bioscience NAGE Stock Holding History

David Shaw’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$319K Sell
99,938
-177,443
-64% -$720K ﹤0.01% 4387
2026
Q1 		$1.22M Sell
277,381
-69,164
-20% -$373K ﹤0.01% 3286
2025
Q4 		$2.2M Sell
346,545
-199,638
-37% -$1.39M ﹤0.01% 2979
2025
Q3 		$5.1M Sell
546,183
-1,055,625
-66% -$10.7M ﹤0.01% 2193
2025
Q2 		$23.1M Buy
1,601,808
+318,018
+25% +$3.14M 0.02% 950
2025
Q1 		$8.86M Buy
1,283,790
+272,500
+27% +$1.71M 0.01% 1487
2024
Q4 		$5.36M Buy
1,011,290
+957,665
+1,786% +$5.24M ﹤0.01% 1920
2024
Q3 		$196K Buy
+53,625
New +$169K ﹤0.01% 4167
2023
Q3 		– Sell
-37,694
Closed -$59.2K – 4543
2023
Q2 		$59.2K Sell
37,694
-58,319
-61% -$87K ﹤0.01% 3867
2023
Q1 		$147K Sell
96,013
-60,433
-39% -$108K ﹤0.01% 3951
2022
Q4 		$263K Buy
156,446
+63,914
+69% +$101K ﹤0.01% 4144
2022
Q3 		$114K Buy
92,532
+25,208
+37% +$40.6K ﹤0.01% 4580
2022
Q2 		$112K Sell
67,324
-18,171
-21% -$35.5K ﹤0.01% 4706
2022
Q1 		$210K Buy
85,495
+23,453
+38% +$64.1K ﹤0.01% 4842
2021
Q4 		$232K Buy
62,042
+15,226
+33% +$82.2K ﹤0.01% 4807
2021
Q3 		$294K Sell
46,816
-41,336
-47% -$341K ﹤0.01% 4364
2021
Q2 		$869K Buy
+88,152
New +$769K ﹤0.01% 3660

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

David Shaw's NAGE Position: Q2 2026 in Review

David Shaw reduced its Niagen Bioscience (NAGE) stake by 64% in Q2 2026, selling an estimated $720K and leaving 99,938 shares worth $319K. The position accounts for ﹤0.01% of the portfolio, ranked #4387.

David Shaw first reported a position in NAGE in Q2 2021 and has held it in 17 quarters since. The position peaked at $23.1M in Q2 2025. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • David Shaw held 99,938 shares of Niagen Bioscience worth $319K as of Q2 2026.
  • David Shaw sold 177,443 Niagen Bioscience shares in Q2 2026, an estimated $720K.
  • Niagen Bioscience made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4387 holding.
  • David Shaw first reported a position in Niagen Bioscience in Q2 2021 and has held it in 17 quarters since.
  • David Shaw's Niagen Bioscience position peaked at $23.1M in Q2 2025.
  • 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.